| Literature DB >> 35788213 |
Rema Panickar1,2, Zoriah Aziz3,4, Adeeba Kamarulzaman1.
Abstract
BACKGROUND: Medication risk communication is essential to ensure the safe use of medicines. However, very few nations worldwide have established effective risk communication systems. To date, the effectiveness of risk communication among healthcare professionals in Malaysia has never been evaluated. Our study aimed to (i) evaluate doctors' and pharmacists' awareness of regulatory risk communication methods; (ii) identify factors predicting the usefulness of these methods; and (iii) compare respondents' preferences for risk communication to outline suggestions for enhancement.Entities:
Keywords: Alerts; Healthcare professionals; Pharmacovigilance; Predictors; Risk minimization; Safety information; Survey
Mesh:
Year: 2022 PMID: 35788213 PMCID: PMC9253255 DOI: 10.1186/s12889-022-13703-x
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 4.135
Characteristics of the four medication risk communication methods included in this study [22, 23]
| Risk communication method | ||||
|---|---|---|---|---|
| MADRAC Bulletin | Safety Alert | DHPC | Educational material | |
| NPRA | NPRA | Product registration holder, reviewed by NPRA | Product registration holder, NPRA, MOH | |
| Healthcare professionals | Healthcare professionals | Healthcare professionals | Healthcare professionals or patients | |
• Email to healthcare professionals in NPRA mailing list, administrative heads of healthcare facilities, professional associations • NPRA website | By product registration holder directly to healthcare professionals who use the product mentioned in DHPC | • By product registration holder or MOH directly to healthcare professionals • By healthcare professionals to patients | ||
• Local ADR case reports • MADRAC activities • Latest pharmacovigilance activities | • Latest or emerging safety issues • Summary of DHPCs | Important changes to medicinal product information. | Additional information to minimize risk of using the product, in addition to package insert information. | |
| Every four months | As required, depending on emerging safety issues. | |||
ADR Adverse drug reaction; DHPC Direct Healthcare Professional Communication letter; MADRAC Malaysian Adverse Drug Reactions Advisory Committee; MOH Ministry of Health; NPRA National Pharmaceutical Regulatory Agency
Socio-demographics of respondents (N = 1146)
| Demographics | Pharmacists ( | Doctors ( | |
|---|---|---|---|
| n (%) | n (%) | ||
| Male | 142 (21.8) | 248 (50.0) | |
| Female | 508 (78.2) | 248 (50.0) | |
| Mean ± SD | 35.6 ± 6.9 | 39.8 ± 9.2 | |
| Range | 25 to 69 | 27 to 75 | |
| Malay | 268 (41.2) | 189 (38.1) | |
| Chinese | 304 (46.8) | 152 (30.6) | |
| Indian | 54 (8.3) | 141 (28.4) | |
| Others | 24 (3.7) | 14 (2.8) | |
| | |||
| Hospital-based | 300 (46.2) | 264 (53.2) | |
| Community-based | 109 (16.8) | 84 (16.9) | |
| Administrative | 113 (17.4) | 50 (10.1) | |
| Others | 4 (0.6) | 3 (0.6) | |
| | |||
| Hospital-based | 40 (6.2) | 30 (6.0) | |
| Community-based | 52 (8.0) | 60 (12.1) | |
| Pharmaceutical industry | 30 (4.6) | 2 (0.4) | |
| Others | 2 (0.3) | 3 (0.6) | |
| Urban | 541 (83.2) | 439 (88.5) | |
| Rural | 109 (16.8) | 57 (11.5) | |
| Mean ± SD | 11.1 ± 6.3 | 14.1 ± 8.5 | |
| Yes | 474 (72.9) | 249 (50.2) | |
| No | 176 (27.1) | 247 (49.8) | |
| Training or courses | 543 (83.5) | 268 (54.0) | |
| Product package inserts or Consumer medication information leaflets | 471 (72.5) | 223 (45.0) | |
| Medicines reference book | 371 (57.1) | 303 (61.0) | 0.172 |
| NPRA website or bulletin | 371 (57.1) | 82 (16.5) | |
| A mobile phone application | 347 (53.4) | 183 (36.9) | |
| Medical journals | 263 (40.5) | 252 (50.8) | |
Statistically significant p-values are shown in bold
NPRA National Pharmaceutical Regulatory Agency, SD Standard deviation
Fig. 1Comparison between doctors and pharmacists on four risk communication methods used in Malaysia. (a) Awareness – “have seen and read it”, (b) Perceived usefulness, (c) How often they take the recommended risk minimization action. Chi-square test, **p < 0.001. DHPCs: Direct Healthcare Professional Communication letters; MADRAC: Malaysian Adverse Drug Reactions Advisory Committee; NPRA: National Pharmaceutical Regulatory Agency
Fig. 2Awareness of public and private sector respondents on four risk communication methods. p-values indicate differences between sectors. Chi-square test, *p < 0.05; **p < 0.001. DHPCs: Direct Healthcare Professional Communication letters; MADRAC: Malaysian Adverse Drug Reactions Advisory Committee; NPRA: National Pharmaceutical Regulatory Agency
Predictors of risk communication usefulness (N = 1146)
| Variables | Univariate regression | Multivariate regression | ||
|---|---|---|---|---|
| Odds ratio (95% CI) | Adjusted odds ratio (95% CI) | |||
| Male | 1 | 1 | ||
| Female | 2.14 (1.66, 2.75) | 1.29 (0.92, 1.78) | 0.140 | |
| < 45 years | 1 | |||
| 45 years and above | 1.16 (0.82, 1.64) | 0.394 | ||
| Chinese | 1 | < 0.001 | 1 | 0.013 |
| Malay | 1.30 (0.98, 1.71) | 0.065 | 1.85 (1.28, 2.68) | |
| Indian | 0.54 (0.38, 0.76) | 1.35 (0.87, 2.09) | 0.184 | |
| Other | 1.42 (0.69, 2.93) | 0.346 | 1.44 (0.59, 3.50) | 0.425 |
| Specialist | 1 | < 0.001 | 1 | < 0.001 |
| General practitioner | 1.84 (0.96, 3.55) | 0.067 | 2.69 (1.06, 6.84) | |
| Medical officer | 0.92 (0.59, 1.44) | 0.703 | 1.07 (0.64, 1.79) | 0.797 |
| Consultant | 2.03 (1.10, 3.76) | 2.06 (1.07, 3.99) | ||
| Pharmacist | 13.97 (9.21, 21.17) | 18.17 (10.98, 30.07) | ||
| Private- community | 1 | < 0.001 | 1 | 0.013 |
| Private- hospital | 1.76 (0.94, 3.30) | 0.077 | 1.96 (0.83, 4.61) | 0.124 |
| Public- community | 1.30 (0.809, 2.08) | 0.281 | 1.53 (0.73, 3.20) | 0.257 |
| Public- hospital | 1.14 (0.76, 1.71) | 0.537 | 1.54 (0.80, 2.97) | 0.192 |
| Public- administrative | 3.18 (1.86, 5.42) | 3.64 (1.66, 7.99) | ||
| Pharma industry | 7.80 (2.24, 27.09) | 4.61 (1.08, 19.72) | ||
| Others | 1.61 (0.46, 5.67) | 0.456 | 1.93 (0.43, 8.62) | 0.388 |
| Urban | 1 | 1 | ||
| Rural | 1.61 (1.12, 2.32) | 1.71 (1.08, 2.72) | ||
| < 5 years | 1 | 0.166 | 1 | < 0.001 |
| 5 to 9 years | 1.02 (0.67, 1.56) | 0.917 | 1.12 (0.65, 1.91) | 0.692 |
| 10 to 29 years | 1.35 (0.93, 1.98) | 0.117 | 2.63 (1.57, 4.42) | |
| 30 years and above | 1.32 (0.66, 2.66) | 0.433 | 4.89 (1.98, 12.08) | |
| No | 1 | 1 | ||
| Yes | 2.66 (2.07, 3.41) | 1.60 (1.16, 2.21) | ||
| Bahasa Melayu | 1 | |||
| English | 1.11 (0.79, 1.57) | 0.545 | ||
Forward LR Multiple Logistic model was applied. Model is fit with Hosmer-Lemeshow test p = 0.903, Classification table = 79.2%. Statistically significant p-values are shown in bold. CI Confidence interval
Preferences of pharmacists and doctors on risk communication (N = 1146)
| Preferences | Pharmacists, n (%) | Doctors, n (%) | χ | |||
|---|---|---|---|---|---|---|
| Public sector | Private sector ( | Public sector | Private sector ( | |||
| English | 438 (83.3) | 120 (96.8) | 334 (83.3) | 89 (93.7) | 0.07 | 0.788 |
| Bahasa Melayu | 88 (16.7) | 4 (3.2) | 67 (16.7) | 6 (6.3) | ||
| Yes | 508 (96.6) | 117 (94.4) | 388 (96.8) | 92 (96.8) | 0.31 | 0.575 |
| Electronic | 383 (72.8) | 94 (75.8) | 242 (60.3) | 60 (63.2) | 29.1 | |
| Hardcopy | 58 (11.0) | 16 (12.9) | 98 (24.4) | 15 (15.8) | ||
| No preference | 85 (16.2) | 14 (11.3) | 61 (15.2) | 20 (21.1) | ||
| Immediate update of individual safety issues | 287 (54.6) | 69 (55.6) | 152 (37.9) | 47 (49.5) | ||
| Weekly update of all safety issues | 91 (17.3) | 35 (28.2) | 71 (17.7) | 19 (20.0) | 0.28 | 0.595 |
| Monthly update of all safety issues | 250 (47.5) | 50 (40.3) | 191 (47.6) | 43 (45.3) | 0.12 | 0.731 |
| Quarterly update of all safety issues | 47 (8.9) | 4 (3.2) | 75 (18.7) | 15 (15.8) | 27.7 | |
| NPRA, Ministry of Health Malaysia | 507 (96.4) | 115 (92.7) | 341 (85.0) | 79 (83.2) | 41.4 | |
| Professional body | 307 (58.4) | 89 (71.8) | 264 (65.8) | 71 (74.7) | 5.33 | |
| International regulatory agency | 294 (55.9) | 68 (54.8) | 197 (49.1) | 45 (47.4) | 5.38 | |
| Pharmaceutical companies | 236 (44.9) | 70 (56.5) | 125 (31.2) | 44 (46.3) | 19.6 | |
| 452 (85.9) | 107 (86.3) | 295 (73.6) | 74 (77.9) | 24.6 | ||
| National clinical guidelines | 232 (44.1) | 40 (32.3) | 182 (45.4) | 53 (55.8) | 3.49 | 0.062 |
| Website | 229 (43.5) | 67 (54.0) | 156 (38.9) | 39 (41.1) | 4.45 | |
| Product package insert | 268 (51.0) | 52 (41.9) | 101 (25.2) | 29 (30.5) | 62.5 | |
| Mobile phone text | 182 (34.6) | 43 (34.7) | 151 (37.7) | 41 (43.2) | 2.04 | 0.153 |
| Social media | 240 (45.6) | 29 (23.4) | 125 (31.2) | 18 (18.9) | 19.3 | |
| Medical journal | 126 (24.0) | 26 (21.0) | 130 (32.4) | 39 (41.1) | 15.9 | |
| Consumer medication information leaflet | 176 (33.5) | 37 (29.8) | 68 (17.0) | 15 (15.8) | 37.8 | |
| information is relevant for daily practice | 405 (77.0) | 86 (69.4) | 297 (74.1) | 69 (72.6) | 0.46 | 0.500 |
| trust the sender of the safety information | 374 (71.1) | 96 (77.4) | 254 (63.3) | 58 (61.1) | 11.5 | |
| the document is not too lengthy | 346 (65.8) | 71 (57.3) | 238 (59.4) | 55 (57.9) | 3.08 | 0.079 |
| the adverse drug reaction is severe or causes irreversible harm | 410 (77.9) | 93 (75.0) | 312 (77.8) | 73 (76.8) | 0.01 | 0.924 |
| receive sufficient background information | 352 (66.9) | 78 (62.9) | 257 (64.1) | 58 (61.1) | 0.87 | 0.352 |
| recommendations are clear | 344 (65.4) | 65 (52.4) | 249 (62.1) | 54 (56.8) | 0.40 | 0.526 |
| information is relevant for daily practice | 332 (63.1) | 61 (49.2) | 237 (59.1) | 52 (54.7) | 0.56 | 0.453 |
| information is incorporated in clinical or professional society guidelines | 266 (50.6) | 45 (36.3) | 223 (55.6) | 52 (54.7) | 6.50 | |
Statistically significant p-values are shown in bold. NPRA National Pharmaceutical Regulatory Agency
Fig. 3Thematic map of healthcare professionals’ perspectives on medication risk communication derived from the current study